GSK vs. ZTS, REGN, VRTX, TAK, GMAB, ALNY, HZNP, BGNE, SNY, and BMY
Should you be buying GSK stock or one of its competitors? The main competitors of GSK include Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TAK), Genmab A/S (GMAB), Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics Public (HZNP), BeiGene (BGNE), Sanofi (SNY), and Bristol-Myers Squibb (BMY). These companies are all part of the "pharmaceutical preparations" industry.
GSK vs.
GSK (NYSE:GSK) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability, institutional ownership and community ranking.
13.2% of GSK shares are held by institutional investors. Comparatively, 90.2% of Zoetis shares are held by institutional investors. 10.0% of GSK shares are held by insiders. Comparatively, 0.1% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
GSK pays an annual dividend of $1.36 per share and has a dividend yield of 4.0%. Zoetis pays an annual dividend of $1.50 per share and has a dividend yield of 0.9%. GSK pays out 16.4% of its earnings in the form of a dividend. Zoetis pays out 33.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.
Zoetis has a consensus target price of $221.14, suggesting a potential upside of 28.66%. Given GSK's higher probable upside, analysts clearly believe GSK is more favorable than Zoetis.
In the previous week, GSK had 2 more articles in the media than Zoetis. MarketBeat recorded 8 mentions for GSK and 6 mentions for Zoetis. GSK's average media sentiment score of 0.59 beat Zoetis' score of 0.54 indicating that GSK is being referred to more favorably in the media.
GSK has a net margin of 47.85% compared to Zoetis' net margin of 25.59%. Zoetis' return on equity of 50.26% beat GSK's return on equity.
GSK has higher revenue and earnings than Zoetis. GSK is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.
GSK has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.
Zoetis received 69 more outperform votes than GSK when rated by MarketBeat users. Likewise, 77.57% of users gave Zoetis an outperform vote while only 56.79% of users gave GSK an outperform vote.
Summary
GSK and Zoetis tied by winning 10 of the 20 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools